Genomovar distribution of the Burkholderia cepacia complex differs significantly between Czech and Slovak patients with cystic fibrosis

Dřevı́nek, Pavel; Cinek, Ondřej; Melter, J.; Langsádl, L; Navesnakova, Yveta; Vávrová, V.

doi:10.1099/jmm.0.05163-0

Cited by 14 publications

(8 citation statements)

References 8 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 13% of the B. cenocepacia isolates belonged to HaeIII-recA RFLP type U, which was reported as a major problem in the Genoa CF center (44). The HaeIII-recA RFLP type U isolates of the This predominance of B. cenocepacia in CF patients in Italy resembles the situation reported in Canada (80% prevalence) (58), the United States (50%) (53), the United Kingdom (76%) (9), and the Prague and Lisbon CF centers in Portugal, with prevalences of 90% and 52%, respectively (17,21). Some national reports showed that other genomovars reach significant percentages, such as B. cepacia (genomovar I) in Australia (29%) (31); B. multivorans in France (51%) (4), the United States (38%) (37), the United Kingdom (39%) (62), and Belgium (18); or B. stabilis (54%) in the Slovak Republic (21).…”

Section: Discussionmentioning

confidence: 67%

Transmission of Burkholderia cepacia Complex: Evidence for New Epidemic Clones Infecting Cystic Fibrosis Patients in Italy

et al. 2005

View full text Add to dashboard Cite

To analyze national prevalence, genomovar distribution, and epidemiology of the Burkholderia cepacia complex in Italy, 225 putative B. cepacia complex isolates were obtained from 225 cystic fibrosis (CF) patients attending 18 CF centers. The genomovar status of these isolates was determined by a polyphasic approach, which included whole-cell protein electrophoresis and recA restriction fragment length polymorphism (RFLP) analysis. Two approaches were used to genotype B. cepacia complex isolates: BOX-PCR fingerprinting and pulsedfield gel electrophoresis (PFGE) of genomic macrorestriction fragments. A total of 208 (92%) of 225 isolates belonged to the B. cepacia complex, with Burkholderia cenocepacia as the most prevalent species (61.1%). Clones delineated by PFGE were predominantly linked to a single center; in contrast, BOX-PCR clones were composed of isolates collected either from the same center or from different CF centers and comprised multiple PFGE clusters. Three BOX-PCR clones appeared of special interest. One clone was composed of 17 B. cenocepacia isolates belonging to recA RFLP type H. These isolates were collected from six centers and represented three PFGE clusters. The presence of insertion sequence IS1363 in all isolates and the comparison with PHDC reference isolates identified this clone as PHDC, an epidemic clone prominent in North American CF patients. The second clone included 22 isolates from eight centers and belonged to recA RFLP type AT. The genomovar status of strains with the latter RFLP type is not known. Most of these isolates belonged to four different PFGE clusters. Finally, a third clone comprised nine B. pyrrocinia isolates belonging to recA RFLP type Se13. They represented three PFGE clusters and were collected in three CF centers.In the late 1970s and 1980s, reports on the recovery of Burkholderia cepacia from cystic fibrosis (CF) specimens began to appear (29), and the emergence of this pathogen was subsequently reviewed (25,35,36). Polyphasic taxonomic studies identified bacteria tentatively classified as B. cepacia as a complex of at least nine closely related species (genomovars). This B. cepacia complex consists of B. cepacia,

show abstract

Section: Discussionmentioning

confidence: 67%

Transmission of Burkholderia cepacia Complex: Evidence for New Epidemic Clones Infecting Cystic Fibrosis Patients in Italy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Shared strains from other species in the B. cepacia complex have been reported and generally involved smaller numbers of patients. 133,161,163,164 A notable exception is B. dolosa strain SLC6, which was identified in an outbreak in a US CF center and associated with deterioration in lung function and increased mortality. 25,133 The Glasgow strain of B. multivorans was identified in an outbreak among people with CF in the city in the early 1990s.…”

Section: Iiia Person-to-person Transmission Among People With Cfmentioning

confidence: 99%

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Saiman

Siegel

LiPuma

et al. 2014

Infect. Control Hosp. Epidemiol.

346

382

View full text Add to dashboard Cite

The 2013 Infection Prevention and Control (IP&C) Guideline for Cystic Fibrosis (CF) was commissioned by the CF Foundation as an update of the 2003 Infection Control Guideline for CF. During the past decade, new knowledge and new challenges provided the following rationale to develop updated IP&C strategies for this unique population:1. The need to integrate relevant recommendations from evidence-based guidelines published since 2003 into IP&C practices for CF. These included guidelines from the Centers for Disease Control and Prevention (CDC)/Healthcare Infection Control Practices Advisory Committee (HICPAC), the World Health Organization (WHO), and key professional societies, including the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). During the past decade, new evidence has led to a renewed emphasis on source containment of potential pathogens and the role played by the contaminated healthcare environment in the transmission of infectious agents. Furthermore, an increased understanding of the importance of the application of implementation science, monitoring adherence, and feedback principles has been shown to increase the effectiveness of IP&C guideline recommendations.2. Experience with emerging pathogens in the non-CF population has expanded our understanding of droplet transmission of respiratory pathogens and can inform IP&C strategies for CF. These pathogens include severe acute respiratory syndrome coronavirus and the 2009 influenza A H1N1. Lessons learned about preventing transmission of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negative pathogens in non-CF patient populations also can inform IP&C strategies for CF.

show abstract

“…Although patients infected with other B. cepacia complex species were identified in these surveys, both studies were performed prior to the identification of B. anthina and B. pyrrocinia as members of the B. cepacia complex. More recent studies from several additional countries have identified various proportions of CF patients infected with species other than B. cenocepacia and B. multivorans, but these studies have involved relatively small numbers of patients (1,(7)(8)(9)(10)13). Thus, the relative proportion of B. cepacia complex species causing human infection, particularly in CF, requires further elucidation.…”

mentioning

confidence: 99%

“…However, these studies have involved much smaller numbers of patients. For example, Drevinek and colleagues (9) found that 13 (54%) of 24 Slovak patients were infected with B. stabilis. Cunha and colleagues (7) identified B. cepacia and B. stabilis in 8 (36%) and 4 (18%) of 22 Portuguese CF patients, respectively.…”

mentioning

confidence: 99%

Distribution of Burkholderia cepacia Complex Species among Isolates Recovered from Persons with or without Cystic Fibrosis

2005

View full text Add to dashboard Cite

show abstract

Genomovar distribution of the Burkholderia cepacia complex differs significantly between Czech and Slovak patients with cystic fibrosis

Cited by 14 publications

References 8 publications

Transmission of Burkholderia cepacia Complex: Evidence for New Epidemic Clones Infecting Cystic Fibrosis Patients in Italy

Transmission of Burkholderia cepacia Complex: Evidence for New Epidemic Clones Infecting Cystic Fibrosis Patients in Italy

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Distribution of Burkholderia cepacia Complex Species among Isolates Recovered from Persons with or without Cystic Fibrosis

Contact Info

Product

Resources

About